Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Niacin
Drug ID BADD_D01559
Description Niacin is a B vitamin used to treat vitamin deficiencies as well as hyperlipidemia, dyslipidemia, hypertriglyceridemia, and to reduce the risk of myocardial infarctions.[L7550,L7553,L7556,L7559,L7562,L7565]
Indications and Usage For the treatment of type IV and V hyperlipidemia. It is indicated as ajunctive therapy.
Marketing Status Prescription; Discontinued
ATC Code C04AC01; C10AD02
DrugBank ID DB00627
KEGG ID D00049
MeSH ID D009525
PubChem ID 938
TTD Drug ID Not Available
NDC Product Code 71740-201; 51407-268; 71741-020; 62175-322; 59746-380; 0074-3274; 25441-0095; 47335-613; 65162-323; 62331-016; 59746-387; 71741-047; 50268-584; 68180-222; 47335-614; 51407-267; 59746-381; 0074-3275; 59651-019; 63629-7193; 72919-420; 59651-018; 59651-020; 71740-001; 62175-320; 0074-3265; 68180-221; 33342-189; 51552-0559; 68180-223; 33342-187; 62704-0027; 47335-539; 65162-322; 65372-1194; 65162-321
Synonyms Niacin | Nicotinic Acid | 3-Pyridinecarboxylic Acid | 3 Pyridinecarboxylic Acid | Niacin Lithium Salt, Hemihydrate | Niacin Potassium Salt | Potassium Salt, Niacin | Niacin Sodium Salt | Sodium Salt, Niacin | Niacin Tartrate | Tartrate, Niacin | Niacin Copper (2+) Salt | Niacin Hydrochloride | Hydrochloride, Niacin | Niacin Iron (2+) Salt | Niacin Tosylate | Tosylate, Niacin | Niacin Zinc Salt | Nicamin | Nico-400 | Nico 400 | Nico400 | Nicobid | Nicocap | Nicolar | Nicotinate | Wampocap | Enduracin | Induracin | Niacin Calcium Salt | Lithium Nicotinate | Nicotinate, Lithium | Niacin Aluminum Salt | Aluminum Salt, Niacin | Niacin Ammonium Salt | Niacin Lithium Salt | Niacin Cobalt (2+) Salt | Niacin Magnesium Salt | Niacin Manganese (2+) Salt
Chemical Information
Molecular Formula C6H5NO2
CAS Registry Number 59-67-6
SMILES C1=CC(=CN=C1)C(=O)O
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Pain08.01.08.004--
Pain in extremity15.03.04.010--
Pain of skin23.03.03.0030.000724%
Palpitations02.01.02.003--
Paraesthesia17.02.06.0050.001447%
Peptic ulcer07.04.07.001--Not Available
Platelet count decreased13.01.04.0010.001085%
Prothrombin time prolonged13.01.02.012--Not Available
Pruritus23.03.12.0010.005065%
Rash23.03.13.0010.003980%Not Available
Rash maculo-papular23.03.13.004--
Rhabdomyolysis15.05.05.0020.001809%
Skin discolouration23.03.03.005--Not Available
Swelling face10.01.05.018; 23.04.01.0180.000724%Not Available
Swollen tongue23.04.01.014; 10.01.05.015; 07.14.02.0030.000724%Not Available
Syncope24.06.02.012; 17.02.04.008; 02.01.02.0080.000724%
Tachycardia02.03.02.0070.000724%Not Available
Thrombocytopenia01.08.01.0020.000724%Not Available
Tinnitus17.04.07.004; 04.04.01.0020.000724%
Tongue oedema23.04.01.009; 10.01.05.008; 07.14.02.007--Not Available
Tremor17.01.06.0020.000724%
Urticaria23.04.02.001; 10.01.06.0010.004342%
Vision blurred17.17.01.010; 06.02.06.007--
Vomiting07.01.07.003--
Blood phosphorus increased13.11.01.016--Not Available
Contusion23.03.11.002; 15.03.01.008; 12.01.06.001; 24.07.06.0010.000724%
Skin burning sensation23.03.03.021; 17.02.06.009--Not Available
Transaminases increased13.03.01.015--Not Available
Hepatic enzyme increased13.03.01.0190.001085%Not Available
Hot flush08.01.03.027; 24.03.01.005; 21.02.02.0010.001809%
The 3th Page    First    Pre   3 4    Next   Last    Total 4 Pages